Fri Jan 22 2021 | Kenny DeJohn | College
Just weeks after the lacrosse community rallied together to raise money for Chris Bocklet and assistant NCAA coaches on the fundraising platform GoFundMe, it has come together yet again.
Colin Clive, a 2014 graduate of Siena from Massapequa (N.Y.), tragically lost both of his parents within the same week. Clive’s mother, Barbara, died from complications of pneumonia. Dave Clive died just days after. He had a heart attack and had a stent put in before going home and suffering a fatal heart attack, Stegner said.
Clive, a former professional soccer player in the United Kingdom, was still working at age 70 to maintain health coverage for his son, who has been battling brain cancer for the past two years. According to the GoFundMe, which was written by Stegner, Clive has recently started an experimental treatment that is successfully fighting the metastatic cancer.
Love Philly? Sign up for the free Billy Penn email newsletter to get everything you need to know about Philadelphia, every day.
It’s understandable if you hadn’t heard of Bala Cynwyd billionaire Jeffrey Yass before this month.
Often referred to as secretive or “stealthy and mysterious,” he owns Susquehanna International Group, a powerful financial and tech trading firm just across the Philly border on City Avenue. Poker is considered a big part of their corporate culture, and the firm reportedly holds a $15 billion stake in TikTok.
CEO Yass was recently linked to conservative political action committee Club for Growth in a report from British news outlet The Guardian.
Toni Recchia Allende, 61, of Vista, NY passed away peacefully with family at her side on January 6, 2021 after a heroic two-and-a-half-year battle with glioblastoma multiforme, a highly aggressive brain cancer. She was a courageous fighter who far outlived her diagnosis.
Toni Recchia Allende
Formerly of New Canaan, CT, Toni was born September 28, 1959 in Settefrati, Italy. She immigrated to the United States with her family in 1965 where they settled in New Canaan. Toni attended East School and was a 1978 graduate of New Canaan High School. In addition to working full time and raising her family, she studied marketing and economics at Norwalk Community College. Before her illness, Toni enjoyed a successful career in publishing and was a highly accomplished, multi-faceted leader, recognized for her keen business insights and her unbelievable energy, focus and drive.
Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
January 08, 2021 06:00 ET | Source: Chimerix, Inc. Chimerix, Inc.
ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma
Compelling Response Rates to Date; Defined Regulatory Path to Registration Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million
Management to Host Conference Call at 8:30 a.m. ET Today
DURHAM, N.C., Jan. 08, 2021 (GLOBE NEWSWIRE) Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has acquired Oncoceutics, Inc., a privately-held, clinical-stage biotechnology company developing imipridones, a novel class of compounds. Oncoceutics’ lead product candidate, ONC201, has been shown in clinical testing to selectively induce c
Posted on 288
Global Coalition for Adaptive Research (LOS ANGELES, CA), Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA, SYDNEY, Australia), and Kintara Therapeutics, Inc. (NASDAQ: KTRA, SAN DIEGO, CA) The Global Coalition for Adaptive Research (GCAR) in collaboration with Kazia and Kintara, today announced the activation of Kazia’s
paxalisib and Kintara’s
VAL-083 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment). GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that tests multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (GBM) – the deadliest form of brain cancer.
Kazia’s
paxalisib and Kintara’s
VAL-083 are entering the GBM AGILE trial, which initially opened in July 2019 and has screened over 370 patients to date.